Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Roberto Latagliata, Valeria Santini et al.|The Lancet Haematology|2017

Cited by 163